CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia

Inclusion Criteria: * Diagnosed with refractory immune-related cytopenia, including immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA); * Age ranging from 18 to 80 years old (inclusive of 18 and 80); * Expected survival time \> 12 months; * Good function of major organs: 1. liver function: ALT/AST \< 3 times the upper limit of normal; 2. kidney function: creatinine \< 100 μmol/L; 3. lung function: indoor oxygen saturation ≥ 95%; 4. heart function: left ventricular ejection fraction (LVEF) ≥ 50%; * Peripheral superficial venous blood flow is unobstructed, capable of meeting the requirements for intravenous infusion; * Karnofsky score ≥ 60, ECOG ≤ 2 points. Exclusion Criteria: * Women who are pregnant (with positive urine/blood pregnancy test results) or breastfeeding; * Those who have severe underlying heart diseases when participating in this study, including: 1. clinically significant atrial fibrillation (AF), 2. cardiac conduction block, 3. myocardial infarction (within 1 year), 4. congestive heart failure (CHF); 5. cardiac echocardiography LVEF \< 50%; 6. New York Heart Association (NYHA) cardiac function classification of III-IV grade; * Those with active bleeding or bleeding tendencies, and those who need to take anticoagulant drugs; * Those with organ dysfunction or uncontrollable coexisting diseases; * History of malignant tumors; * Those with active chronic hepatitis B or active hepatitis C; * Known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome; * Those with uncontrollable infectious diseases; * As determined by the investigator, other unsuitable conditions exist.